Status:

UNKNOWN

Follow-up After TAVR Without Systematic Intensive Care Unit Admission

Lead Sponsor:

University Hospital, Montpellier

Conditions:

Aortic Valve Stenosis

Eligibility:

All Genders

18+ years

Brief Summary

Since the first case described in 2002, TAVI (transcatheter Aortic Valve Implantation) revolutionized the management of severe symptomatic aortic stenosis. Initially reserved for patients with prohibi...

Detailed Description

Since the first case described in 2002, indications of TAVI (transcatheter Aortic Valve Implantation) procedures increased in the treatment of symptomatic severe aortic stenosis. Initially reserved fo...

Eligibility Criteria

Inclusion

  • Inclusion criteria:
  • age \> 18 yo
  • Patients undergoing a TAVI at Montpellier University Hospital since 2017
  • With implantation of a COREVALVE or EDWARDS
  • Exclusion criteria:
  • Minor patient
  • Patient unable to give consent for reasons of understanding or language barrier
  • Death before unit admission
  • Patients referred to a non cardiological unit after the procedure

Exclusion

    Key Trial Info

    Start Date :

    January 1 2017

    Trial Type :

    OBSERVATIONAL

    Allocation :

    ACTUAL

    End Date :

    December 1 2022

    Estimated Enrollment :

    1000 Patients enrolled

    Trial Details

    Trial ID

    NCT04335149

    Start Date

    January 1 2017

    End Date

    December 1 2022

    Last Update

    May 6 2021

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Uhmontpellier

    Montpellier, France, 34295